WO2009127642A3 - Use of lrrk2 inhibitors for neurodegenerative diseases - Google Patents

Use of lrrk2 inhibitors for neurodegenerative diseases Download PDF

Info

Publication number
WO2009127642A3
WO2009127642A3 PCT/EP2009/054436 EP2009054436W WO2009127642A3 WO 2009127642 A3 WO2009127642 A3 WO 2009127642A3 EP 2009054436 W EP2009054436 W EP 2009054436W WO 2009127642 A3 WO2009127642 A3 WO 2009127642A3
Authority
WO
WIPO (PCT)
Prior art keywords
neurodegenerative diseases
lrrk2
compounds
lrrk2 inhibitors
inhibitors
Prior art date
Application number
PCT/EP2009/054436
Other languages
French (fr)
Other versions
WO2009127642A2 (en
Inventor
Nigel Ramsden
Original Assignee
Cellzome Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cellzome Limited filed Critical Cellzome Limited
Publication of WO2009127642A2 publication Critical patent/WO2009127642A2/en
Publication of WO2009127642A3 publication Critical patent/WO2009127642A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention relates to compounds of formula (I), wherein R1 to R9 and R4a have the meaning as cited in the description and the claims for use in a for use in a method of treating or preventing diseases and disorders associated with LRRK2. Said compounds are useful as inhibitors of LRRK2 for the treatment or prophylaxis of neurodegenerative diseases, like Parkinson's disease or Alzheimer's disease. The invention also relates to the preparation of such compounds.
PCT/EP2009/054436 2008-04-15 2009-04-15 Use of lrrk2 inhibitors for neurodegenerative diseases WO2009127642A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP08154538.6 2008-04-15
EP08154538 2008-04-15

Publications (2)

Publication Number Publication Date
WO2009127642A2 WO2009127642A2 (en) 2009-10-22
WO2009127642A3 true WO2009127642A3 (en) 2009-12-10

Family

ID=39735500

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2009/054436 WO2009127642A2 (en) 2008-04-15 2009-04-15 Use of lrrk2 inhibitors for neurodegenerative diseases

Country Status (1)

Country Link
WO (1) WO2009127642A2 (en)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9273077B2 (en) 2008-05-21 2016-03-01 Ariad Pharmaceuticals, Inc. Phosphorus derivatives as kinase inhibitors
LT2300013T (en) 2008-05-21 2017-12-27 Ariad Pharmaceuticals, Inc. Phosphorous derivatives as kinase inhibitors
US11351168B1 (en) 2008-06-27 2022-06-07 Celgene Car Llc 2,4-disubstituted pyrimidines useful as kinase inhibitors
US8338439B2 (en) 2008-06-27 2012-12-25 Celgene Avilomics Research, Inc. 2,4-disubstituted pyrimidines useful as kinase inhibitors
NZ624345A (en) 2008-06-27 2016-07-29 Celgene Avilomics Res Inc 2,4-disubstituted pyrimidines useful as kinase inhibitors
EP2440559B1 (en) 2009-05-05 2018-01-10 Dana-Farber Cancer Institute, Inc. Egfr inhibitors and methods of treating disorders
CA2771675A1 (en) 2009-09-11 2011-03-17 Cellzome Limited Ortho substituted pyrimidine compounds as jak inhibitors
CN105837519A (en) * 2010-06-04 2016-08-10 霍夫曼-拉罗奇有限公司 Aminopyrimidine derivatives as lrrk2 modulators
CN105566229A (en) 2010-08-10 2016-05-11 西建阿维拉米斯研究公司 Besylate salt of a BTK inhibitor, application and preparation method thereof
ES2524892T3 (en) 2010-09-02 2014-12-15 Glaxosmithkline Intellectual Property Development Limited 2- (Benzyloxy) benzamides as inhibitors of LRRK2 kinase
WO2012061299A1 (en) 2010-11-01 2012-05-10 Avila Therapeutics, Inc. Heterocyclic compounds and uses thereof
US9238629B2 (en) 2010-11-01 2016-01-19 Celgene Avilomics Research, Inc. Heteroaryl compounds and uses thereof
RS56583B1 (en) * 2010-11-10 2018-02-28 Genentech Inc Pyrazole aminopyrimidine derivatives as lrrk2 modulators
US8796255B2 (en) 2010-11-10 2014-08-05 Celgene Avilomics Research, Inc Mutant-selective EGFR inhibitors and uses thereof
WO2012118679A1 (en) * 2011-02-28 2012-09-07 Merck Sharp & Dohme Corp. Compounds inhibiting leucine-rich repeat kinase enzyme activity
CN103501612B (en) 2011-05-04 2017-03-29 阿里亚德医药股份有限公司 The compound that cell is bred in cancer caused by suppression EGF-R ELISA
AU2012258977A1 (en) 2011-05-23 2014-01-16 Imago Pharmaceuticals, Inc. Inhibitors of LRRK2 kinase activity
CA2853498A1 (en) 2011-10-28 2013-05-02 Celgene Avilomics Research, Inc. Methods of treating a bruton's tyrosine kinase disease or disorder
CA2850594C (en) * 2011-11-29 2020-03-10 F. Hoffmann-La Roche Ag Aminopyrimidine derivatives as lrrk2 modulators
US9145402B2 (en) * 2011-11-29 2015-09-29 Genentech, Inc. Aminopyrimidine derivatives as LRRK2 modulators
AR089182A1 (en) * 2011-11-29 2014-08-06 Hoffmann La Roche AMINOPIRIMIDINE DERIVATIVES AS MODULATORS OF LRRK2
BR112014009717B1 (en) * 2011-11-29 2022-06-14 Genentech, Inc 2-(PHENYL OR PYRID-3-YL)AMINOPYRIMIDINE DERIVATIVES, THEIR USES, AND PHARMACEUTICAL COMPOSITION
CA2856002C (en) * 2011-11-30 2020-10-13 Bryan K. Chan Fluorine-18 and carbon-11 labeled radioligands for positron emission tomography (pet) imaging for lrrk2
WO2013138495A1 (en) 2012-03-15 2013-09-19 Celgene Avilomics Research, Inc. Solid forms of an epidermal growth factor receptor kinase inhibitor
SI2825042T1 (en) 2012-03-15 2019-01-31 Celgene Car Llc Salts of an epidermal growth factor receptor kinase inhibitor
WO2013169401A1 (en) 2012-05-05 2013-11-14 Ariad Pharmaceuticals, Inc. Compounds for inhibiting cell proliferation in egfr-driven cancers
CN105732639A (en) 2012-06-29 2016-07-06 辉瑞大药厂 Novel 4-(Substituted Amino)-7H-Pyrrolo[2,3-d] Pyrimidines As LRRK2 Inhibitors
US9126950B2 (en) 2012-12-21 2015-09-08 Celgene Avilomics Research, Inc. Heteroaryl compounds and uses thereof
WO2014124230A2 (en) 2013-02-08 2014-08-14 Celgene Avilomics Research, Inc. Erk inhibitors and uses thereof
US9611283B1 (en) 2013-04-10 2017-04-04 Ariad Pharmaceuticals, Inc. Methods for inhibiting cell proliferation in ALK-driven cancers
US9492471B2 (en) 2013-08-27 2016-11-15 Celgene Avilomics Research, Inc. Methods of treating a disease or disorder associated with Bruton'S Tyrosine Kinase
EP3083618B1 (en) 2013-12-17 2018-02-21 Pfizer Inc Novel 3,4-disubstituted-1h-pyrrolo[2,3-b]pyridines and 4,5-disubstituted-7h-pyrrolo[2,3-c]pyridazines as lrrk2 inhibitors
US9415049B2 (en) 2013-12-20 2016-08-16 Celgene Avilomics Research, Inc. Heteroaryl compounds and uses thereof
DK3179858T3 (en) 2014-08-13 2019-07-22 Celgene Car Llc Forms and compositions of an ERK inhibitor
WO2016029002A2 (en) * 2014-08-22 2016-02-25 Clovis Oncology, Inc. Growth factor receptor inhibitors
SG11201701936WA (en) 2014-09-17 2017-04-27 Oncodesign Sa Macrocyclic lrrk2 kinase inhibitors
JP6873980B2 (en) 2015-09-14 2021-05-19 ファイザー・インク Novel imidazole [4,5-c] quinoline and imidazole [4,5-c] [1,5] naphthylidine derivatives as LRRK2 inhibitors
WO2017087905A1 (en) 2015-11-20 2017-05-26 Denali Therapeutics Inc. Compound, compositions, and methods
CN108934162A (en) 2015-12-16 2018-12-04 南方研究所 Pyrrolopyrimidine compounds, as purposes of kinases LRRK2 inhibitor and preparation method thereof
US11028080B2 (en) 2016-03-11 2021-06-08 Denali Therapeutics Inc. Substituted pyrimidines as LRKK2 inhibitors
HUE056678T2 (en) 2016-06-16 2022-02-28 Denali Therapeutics Inc Pyrimidin-2-ylamino-1h-pyrazols as lrrk2 inhibitors for use in the treatment of neurodegenerative disorders
CN110678182B (en) 2017-02-24 2022-08-23 大邱庆北尖端医疗产业振兴财团 Pharmaceutical composition containing a compound capable of penetrating the blood-brain barrier as an active ingredient for preventing or treating brain cancer
JOP20190281A1 (en) 2017-06-13 2019-12-02 Korea Res Inst Chemical Tech N2,n4-diphenylpyrimidin-2,4-diamine derivative, method for preparing same, and pharmaceutical composition containing same as active ingredient for prevention or treatment of cancer
WO2019201334A1 (en) * 2018-04-20 2019-10-24 南京明德新药研发有限公司 Dimethylphosphine oxide compound
CN114302878A (en) 2019-07-03 2022-04-08 大日本住友制药肿瘤公司 Tyrosine kinase non-receptor 1(TNK1) inhibitors and uses thereof
CN113896744B (en) * 2020-07-06 2024-04-16 成都先导药物开发股份有限公司 Selective EGFR inhibitor
CN112225703B (en) * 2020-09-28 2022-03-11 广州智睿医药科技有限公司 Medicine for treating or preventing diseases related to LRRK2 kinase or abnormal LRRK2 mutant kinase activity
CN113831321B (en) * 2021-09-18 2023-01-31 安润医药科技（苏州）有限公司 Small molecule inhibitor of leucine-rich repeat kinase 2 and application thereof
WO2023076404A1 (en) 2021-10-27 2023-05-04 Aria Pharmaceuticals, Inc. Methods for treating systemic lupus erythematosus
WO2023078411A1 (en) * 2021-11-05 2023-05-11 南京明德新药研发有限公司 Azaspiro compound
WO2024030504A1 (en) * 2022-08-02 2024-02-08 Neuron23, Inc. Predictive biomarkers and use thereof to treat parkinson's disease

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004074244A2 (en) * 2003-02-20 2004-09-02 Smithkline Beecham Corporation Pyrimidine compounds
WO2004080980A1 (en) * 2003-03-14 2004-09-23 Novartis Ag 2, 4- di (phenylamino) pyrimidines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders
WO2005026158A1 (en) * 2003-09-16 2005-03-24 Novartis Ag 2,4 di (hetero) -arylamino-pyrimidine derivatives as zap-70 and/or syk inhibitors
WO2005026130A1 (en) * 2003-09-18 2005-03-24 Novartis Ag 2,4-di (phenylamino) pyrimidines useful in the treatment of proliferative disorders
EP1598343A1 (en) * 2004-05-19 2005-11-23 Boehringer Ingelheim International GmbH 2-Arylaminopyrimidine derivatives as PLK inhibitors
WO2006021454A2 (en) * 2004-08-27 2006-03-02 Novartis Ag Pyrimidine derivatives
WO2007120339A1 (en) * 2005-12-19 2007-10-25 Genentech, Inc. Pyrimidine kinase inhibitors
WO2008051547A1 (en) * 2006-10-23 2008-05-02 Cephalon, Inc. Fused bicyclic derivatives of 2,4-diaminopyrimidine as alk and c-met inhibitors
WO2008073687A2 (en) * 2006-12-08 2008-06-19 Irm Llc Compounds and compositions as protein kinase inhibitors
WO2008092049A1 (en) * 2007-01-26 2008-07-31 Smithkline Beecham Corporation Anthranilamide inhibitors of aurora kinase

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004074244A2 (en) * 2003-02-20 2004-09-02 Smithkline Beecham Corporation Pyrimidine compounds
WO2004080980A1 (en) * 2003-03-14 2004-09-23 Novartis Ag 2, 4- di (phenylamino) pyrimidines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders
WO2005026158A1 (en) * 2003-09-16 2005-03-24 Novartis Ag 2,4 di (hetero) -arylamino-pyrimidine derivatives as zap-70 and/or syk inhibitors
WO2005026130A1 (en) * 2003-09-18 2005-03-24 Novartis Ag 2,4-di (phenylamino) pyrimidines useful in the treatment of proliferative disorders
EP1598343A1 (en) * 2004-05-19 2005-11-23 Boehringer Ingelheim International GmbH 2-Arylaminopyrimidine derivatives as PLK inhibitors
WO2006021454A2 (en) * 2004-08-27 2006-03-02 Novartis Ag Pyrimidine derivatives
WO2007120339A1 (en) * 2005-12-19 2007-10-25 Genentech, Inc. Pyrimidine kinase inhibitors
WO2008051547A1 (en) * 2006-10-23 2008-05-02 Cephalon, Inc. Fused bicyclic derivatives of 2,4-diaminopyrimidine as alk and c-met inhibitors
WO2008073687A2 (en) * 2006-12-08 2008-06-19 Irm Llc Compounds and compositions as protein kinase inhibitors
WO2008092049A1 (en) * 2007-01-26 2008-07-31 Smithkline Beecham Corporation Anthranilamide inhibitors of aurora kinase

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DATABASE PATENT CHEMISTRY DATABASE [online] Elsevier Information Systems GmbH, DE; 2008, XP002496194, Database accession no. 463002 (Citation Accession Number) *
LIU ET AL: "Discovery of a new class of 4-anilinopyrimidines as potent c-Jun N-terminal kinase inhibitors: Synthesis and SAR studies", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, PERGAMON, GB, vol. 17, no. 3, 19 January 2007 (2007-01-19), pages 668 - 672, XP005835915, ISSN: 0960-894X *

Also Published As

Publication number Publication date
WO2009127642A2 (en) 2009-10-22

Similar Documents

Publication Publication Date Title
WO2009127642A3 (en) Use of lrrk2 inhibitors for neurodegenerative diseases
MX2010002312A (en) Triazolopyridine compounds and their use as ask inhibitors.
SG179120A1 (en) Novel compounds
WO2010030813A3 (en) Methods for inhibiting ocular angiogenesis
WO2012162254A8 (en) Inhibitors of lrrk2 kinase activity
WO2009011850A3 (en) Novel therapeutic compounds
WO2008104978A3 (en) Novel sirna structures
WO2008006547A3 (en) Pyrrolopyrimidines for pharmaceutical compositions
WO2008094737A3 (en) Purine compounds and compositions as kinase inhibitors for the treatment of plasmodium related diseases
MA32889B1 (en) Pyrazine compounds act as phosphodiesterase 10 inhibitors
WO2008094992A3 (en) 2-aminopyridine derivatives useful as kinase inhibitors
WO2009108383A3 (en) Substituted xanthine derivatives
WO2010083207A3 (en) Protein kinase c inhibitors and uses thereof
MX2009010407A (en) Fluorinated derivatives of deferiprone.
WO2012048129A3 (en) Inhibitors of polo-like kinase
WO2007109279A3 (en) Tetrahydropyridothienopyrimidine compounds and methods of use thereof
WO2010033701A3 (en) Inhibitors of sphingosine kinase 1
WO2009067493A3 (en) 1,3,5 tri-subtituted benzenes for treatment of alzheimer's disease and other disorders
MX2011013032A (en) Inhibitors of phosphatidylinositol 3-kinase.
EP2977452A3 (en) Methods of treatment and prevention of neurodegenerative diseases and disorders
WO2010075280A3 (en) Coumarin-based compounds for the treatment of alzheimer's disease and cancer
MX368459B (en) Novel compositions for preventing and/or treating degenerative disorders of the central nervous system.
WO2007136741A3 (en) N-desmethyl-doxepin and methods of using the same to treat sleep disorders
WO2008121386A3 (en) Calcimimetic compounds for use in the treatment of bowel disorders
MX2011008645A (en) Tetrahydrothiazolopyridine inhibitors of phosphatidylinositol 3-kinase.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09733637

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09733637

Country of ref document: EP

Kind code of ref document: A2